4 completed, 1 enrolling by invitation, 1 suspended, 1 terminated. 4 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Suspended 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow MELAS: new trials by email Literature Review of MELAS trials Research Report on MELAS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| The KHENERGYC Study Sonlicromanol, Placebo - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Suspended | Khondrion BV | 24 | 2021-02-01 | 2025-01-10 |
| Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) IW-6463 Tablets - MELAS | Phase 2 | Terminated | Tisento Therapeutics | 8 | 2020-11-13 | 2024-08-29 |
| Nicotinamide Riboside and Mitochondrial Biogenesis Nicotinamide Riboside - Mitochondrial Diseases, Mitochondrial Myopathies | Not applicable | Completed | Cambridge University Hospitals NHS Foundation Trust | 13 | 2017-12-08 | 2023-07-20 |
| The KHENERGY Study KH176, placebo - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 2 | Completed | Khondrion BV | 20 | 2016-09-01 | 2018-02-23 |
| A Dose-escalating Clinical Trial With KH176 KH176, placebo - MELAS, LHON | Phase 1 | Completed | Khondrion BV | 32 | 2015-05-01 | 2021-10-18 |
| Tissue Sample Study for Mitochondrial Disorders Mitochondrial Disorders, Mitochondrial Disease | Enrolling by invitation | Columbia University | 6900 | 2012-02-01 | 2026-01-07 |
MELAS Syndrome (7) · Mitochondrial Diseases (7) · Leigh Disease (3) · Mitochondrial Myopathies (3) · Mitochondrial Encephalomyopathies (2) · MERRF Syndrome (1) · Ophthalmoplegia, Chronic Progressive External (1)
Brain Diseases (7) · Brain Diseases, Metabolic (7) · Brain Diseases, Metabolic, Inborn (7) · Cardiovascular Diseases (7) · Central Nervous System Diseases (7) · Cerebral Small Vessel Diseases (7) · Cerebrovascular Disorders (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Metabolic Diseases (7) · Metabolism, Inborn Errors (7) · Muscular Diseases (7) · Musculoskeletal Diseases (7) · Nervous System Diseases (7) · Neuromuscular Diseases (7)
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (3) · nicotinamide-beta-riboside (1)
Khondrion BV (3) · Cambridge University Hospitals NHS Foundation Trust (1) · Children's Hospital of Philadelphia (1) · Columbia University (1) · Tisento Therapeutics (1)
United States (3) · Netherlands (2) · Belgium (1) · United Kingdom (1)
Chad Glasser, PharmD (1) · Elizabeth M McCormick, MS (1) · Lonneke de Boer, MD (1) · Michio Hirano, MD (1) · Patrick Chinnery, Prof. (1)
PMID 29037240, PMID 30058726, PMID 35477351
P01HD032062 (1), U54NS078059 (1)